Long-Term Subjective and Objective Assessment of Smell and Taste in COVID-19
Among the first clinical symptoms of the SARS-CoV-2 infection is olfactory−gustatory deficit; this continues for weeks and, in some cases, can be persistent. We prospectively evaluated 162 patients affected by COVID-19 using a visual analogue scale (VAS) for nasal and olfactory−gustatory symptoms. Patients were checked after 7, 14, 21, 28, 90, and 180 days. A total of 118 patients (72.8%) reported an olfactory VAS < 7 at baseline (group B), and 44 (27.2%) reported anosmia (VAS ≥ 7) (group A) and underwent the Brief Smell Identification Test (B-SIT) and Burghart Taste Strips (BTS) to quantify the deficit objectively and repeated the tests to confirm the sense recovery. Group A patients showed B-SIT anosmia and hyposmia in 44.2% and 55.8% of cases, respectively. A total of 88.6% of group A patients reported ageusia with VAS ≥ 7, and BTS confirmed 81.8% of ageusia and 18.2% of hypogeusia. VAS smell recovery was recorded starting from 14 days, with normalization at 28 days. The 28-day B-SIT score showed normosmia in 90.6% of group A patients. The mean time for full recovery (VAS = 0) was shorter in group B (22.9 days) than in group A (31.9 days). Chemosensory deficit is frequently the first symptom in patients with COVID-19, and, in most cases, recovery occurs after four weeks.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Cells - 11(2022), 5 vom: 24. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ciofalo, Andrea [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 08.04.2022 Date Revised 08.03.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/cells11050788 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM338002588 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM338002588 | ||
| 003 | DE-627 | ||
| 005 | 20231225235706.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/cells11050788 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1126.xml |
| 035 | |a (DE-627)NLM338002588 | ||
| 035 | |a (NLM)35269410 | ||
| 035 | |a (PII)788 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ciofalo, Andrea |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Long-Term Subjective and Objective Assessment of Smell and Taste in COVID-19 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.04.2022 | ||
| 500 | |a Date Revised 08.03.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Among the first clinical symptoms of the SARS-CoV-2 infection is olfactory−gustatory deficit; this continues for weeks and, in some cases, can be persistent. We prospectively evaluated 162 patients affected by COVID-19 using a visual analogue scale (VAS) for nasal and olfactory−gustatory symptoms. Patients were checked after 7, 14, 21, 28, 90, and 180 days. A total of 118 patients (72.8%) reported an olfactory VAS < 7 at baseline (group B), and 44 (27.2%) reported anosmia (VAS ≥ 7) (group A) and underwent the Brief Smell Identification Test (B-SIT) and Burghart Taste Strips (BTS) to quantify the deficit objectively and repeated the tests to confirm the sense recovery. Group A patients showed B-SIT anosmia and hyposmia in 44.2% and 55.8% of cases, respectively. A total of 88.6% of group A patients reported ageusia with VAS ≥ 7, and BTS confirmed 81.8% of ageusia and 18.2% of hypogeusia. VAS smell recovery was recorded starting from 14 days, with normalization at 28 days. The 28-day B-SIT score showed normosmia in 90.6% of group A patients. The mean time for full recovery (VAS = 0) was shorter in group B (22.9 days) than in group A (31.9 days). Chemosensory deficit is frequently the first symptom in patients with COVID-19, and, in most cases, recovery occurs after four weeks | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a B-SIT | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a smell | |
| 650 | 4 | |a taste | |
| 650 | 4 | |a taste strips | |
| 700 | 1 | |a Cavaliere, Carlo |e verfasserin |4 aut | |
| 700 | 1 | |a Masieri, Simonetta |e verfasserin |4 aut | |
| 700 | 1 | |a Di Chicco, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Fatuzzo, Irene |e verfasserin |4 aut | |
| 700 | 1 | |a Lo Re, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Baroncelli, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Begvarfaj, Elona |e verfasserin |4 aut | |
| 700 | 1 | |a Adduci, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Mezzaroma, Ivano |e verfasserin |4 aut | |
| 700 | 1 | |a Mastroianni, Claudio Maria |e verfasserin |4 aut | |
| 700 | 1 | |a de Vincentiis, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Greco, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Zamai, Loris |e verfasserin |4 aut | |
| 700 | 1 | |a Artico, Marco |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cells |d 2011 |g 11(2022), 5 vom: 24. Feb. |w (DE-627)NLM227066421 |x 2073-4409 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2022 |g number:5 |g day:24 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/cells11050788 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2022 |e 5 |b 24 |c 02 | ||